CureVac Revenue and Competitors

We fight for human health – the RNA people CureVac is a leading clinical stage biotechnology company in the field of messenger RNA (mRNA) technology with 20 years of expertise in developing and optimizing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, antibody therapies, the treatment of rare diseases, and prophylactic vaccines. CureVac has received significant investments, amongst others from dievini Hopp BioTech holding, the Bill & Melinda Gates Foundation and the German Kreditanstalt für Wiederaufbau (KfW). CureVac has also entered into collaborations with multinational corporations and organizations, including Boehringer Ingelheim, GlaxoSmithKline, Genmab, CRISPR Therapeutics, the Bill & Melinda Gates Foundation, CEPI and others. CureVac is headquartered in Tübingen, Germany with sites in Frankfurt and Boston, USA. Do you want to create progress with us? CureVac's employees are passionate about RNA technology. An extreme amount of heart and soul, enthusiasm and competitive spirit has gone into our company. Shape tomorrow's therapeutic world with us - apply via our career portal: https://career.curevac.com/eng Legal notice: curevac.com/editor Data Privacy Statement: https://www.curevac.com/de/datenschutz/